Bifogade filer
Kurs
-0,12%
Likviditet
2,35 MSEK
Kalender
Est. tid* | ||
2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-30 | N/A | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2025-05-28 | N/A | Årsstämma |
2025-05-15 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-10-30 | - | Split EXPRS2 40:1 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2024-06-05 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-16 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2023-05-24 | - | Årsstämma |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-03-23 | - | Extra Bolagsstämma 2023 |
2023-02-09 | - | Bokslutskommuniké 2022 |
2022-11-17 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2022-05-25 | - | Årsstämma |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-09-23 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-20 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2019-05-23 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-22 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2018-05-24 | - | Årsstämma |
2018-05-17 | - | Kvartalsrapport 2018-Q1 |
2018-02-07 | - | Bokslutskommuniké 2017 |
2017-11-30 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2017-05-31 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-04-19 | - | Extra Bolagsstämma 2017 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, August 15, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include a presentation of Q2 2022 results (August 18), the LSX Nordic Investor Conference (September 6-7), and PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
Presentation of Q2 2022 results at the H.C. Andersen Capital webinar, August 18 at 14:00 CET
ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q2 2022 results and answer investors' questions. More information and registration can be found on the H.C. Andersen Capital events website (https://hcandersencapital.dk/event/expres2ion-biotechnologies-presentation-of-h1-2022/).
LSX Nordic Congress, September 6-7, Copenhagen, Denmark
An opportunity for investors and potential partners to meet ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander in 1-on-1 meetings. More information and registration can be found on the LSX Nordic website (https://www.lsxleaders.com/lsx-nordic-congress).
Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy
Meet ExpreS[2]ion's VP of Preclinical Development, Dr. Mette Thorn, and hear the company's preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine," in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the PIVAC-22 website (https://www.pivac22.it/).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com